AKT-independent phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase signaling by prostaglandin F2α

Edward W. Arvisais, Angela Romanelli, Xiaoying Hou, John S Davis

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Prostaglandin F2α (PGF2α) is an important mediator of corpus luteum (CL) regression, although the cellular signaling events that mediate this process have not been clearly identified. It is established that PGF2α binds to a G-protein coupled receptor (GPCR) to stimulate protein kinase C (PKC) and Raf-MEK-Erk signaling in luteal cells. The present experiments were performed to determine whether PGF2α stimulates the mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase 1 (S6K1) signaling pathway in steroidogenic luteal cells. We demonstrate that PGF2α treatment results in a time- and concentration-dependent stimulation of the phosphorylation and activation of S6K1. The stimulation of S6K1 in response to PGF2α treatment was abolished by the mTOR inhibitor rapamycin. Treatment with PGF2α did not increase AKT phosphorylation but increased the phosphorylation of Erk and the tumor suppressor protein tuberous sclerosis complex 2 (TSC2), an upstream regulator of mTOR. The effects of PGF2α were mimicked by the PKC activator PMA and inhibited by U0126, a MEK1 inhibitor. The activation of mTOR/S6K1 and putative down stream processes involving the translational apparatus (i.e. 4EBP1 phosphorylation, release of 4EBP1 binding in m7G cap binding assays, and the phosphorylation and synthesis of S6) were completely sensitive to treatment with rapamycin, implicating mTOR in the actions of PGF2α. Taken together, our data suggest that GPCR activation in response to PGF2α stimulates the mTOR pathway which increases the translational machinery in luteal cells. The translation of proteins under the control of mTOR may have implications for luteal development and regression and offer new strategies for therapeutic intervention in PGF2α-target tissues.

Original languageEnglish (US)
Pages (from-to)26904-26913
Number of pages10
JournalJournal of Biological Chemistry
Volume281
Issue number37
DOIs
StatePublished - Sep 15 2006

Fingerprint

TOR Serine-Threonine Kinases
Ribosomal Protein S6 Kinases
Phosphorylation
Tuberous Sclerosis
Dinoprost
Sirolimus
Chemical activation
Luteal Cells
Luteolysis
G-Protein-Coupled Receptors
Protein Kinase C
Tuberous Sclerosis 2
Cell signaling
Tumor Suppressor Proteins
S 6
Mitogen-Activated Protein Kinase Kinases
Protein Biosynthesis
Machinery
Assays

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

AKT-independent phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase signaling by prostaglandin F2α. / Arvisais, Edward W.; Romanelli, Angela; Hou, Xiaoying; Davis, John S.

In: Journal of Biological Chemistry, Vol. 281, No. 37, 15.09.2006, p. 26904-26913.

Research output: Contribution to journalArticle

@article{e8fc9f2f220e44caa5ebb6b9cf256507,
title = "AKT-independent phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase signaling by prostaglandin F2α",
abstract = "Prostaglandin F2α (PGF2α) is an important mediator of corpus luteum (CL) regression, although the cellular signaling events that mediate this process have not been clearly identified. It is established that PGF2α binds to a G-protein coupled receptor (GPCR) to stimulate protein kinase C (PKC) and Raf-MEK-Erk signaling in luteal cells. The present experiments were performed to determine whether PGF2α stimulates the mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase 1 (S6K1) signaling pathway in steroidogenic luteal cells. We demonstrate that PGF2α treatment results in a time- and concentration-dependent stimulation of the phosphorylation and activation of S6K1. The stimulation of S6K1 in response to PGF2α treatment was abolished by the mTOR inhibitor rapamycin. Treatment with PGF2α did not increase AKT phosphorylation but increased the phosphorylation of Erk and the tumor suppressor protein tuberous sclerosis complex 2 (TSC2), an upstream regulator of mTOR. The effects of PGF2α were mimicked by the PKC activator PMA and inhibited by U0126, a MEK1 inhibitor. The activation of mTOR/S6K1 and putative down stream processes involving the translational apparatus (i.e. 4EBP1 phosphorylation, release of 4EBP1 binding in m7G cap binding assays, and the phosphorylation and synthesis of S6) were completely sensitive to treatment with rapamycin, implicating mTOR in the actions of PGF2α. Taken together, our data suggest that GPCR activation in response to PGF2α stimulates the mTOR pathway which increases the translational machinery in luteal cells. The translation of proteins under the control of mTOR may have implications for luteal development and regression and offer new strategies for therapeutic intervention in PGF2α-target tissues.",
author = "Arvisais, {Edward W.} and Angela Romanelli and Xiaoying Hou and Davis, {John S}",
year = "2006",
month = "9",
day = "15",
doi = "10.1074/jbc.M605371200",
language = "English (US)",
volume = "281",
pages = "26904--26913",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "37",

}

TY - JOUR

T1 - AKT-independent phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase signaling by prostaglandin F2α

AU - Arvisais, Edward W.

AU - Romanelli, Angela

AU - Hou, Xiaoying

AU - Davis, John S

PY - 2006/9/15

Y1 - 2006/9/15

N2 - Prostaglandin F2α (PGF2α) is an important mediator of corpus luteum (CL) regression, although the cellular signaling events that mediate this process have not been clearly identified. It is established that PGF2α binds to a G-protein coupled receptor (GPCR) to stimulate protein kinase C (PKC) and Raf-MEK-Erk signaling in luteal cells. The present experiments were performed to determine whether PGF2α stimulates the mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase 1 (S6K1) signaling pathway in steroidogenic luteal cells. We demonstrate that PGF2α treatment results in a time- and concentration-dependent stimulation of the phosphorylation and activation of S6K1. The stimulation of S6K1 in response to PGF2α treatment was abolished by the mTOR inhibitor rapamycin. Treatment with PGF2α did not increase AKT phosphorylation but increased the phosphorylation of Erk and the tumor suppressor protein tuberous sclerosis complex 2 (TSC2), an upstream regulator of mTOR. The effects of PGF2α were mimicked by the PKC activator PMA and inhibited by U0126, a MEK1 inhibitor. The activation of mTOR/S6K1 and putative down stream processes involving the translational apparatus (i.e. 4EBP1 phosphorylation, release of 4EBP1 binding in m7G cap binding assays, and the phosphorylation and synthesis of S6) were completely sensitive to treatment with rapamycin, implicating mTOR in the actions of PGF2α. Taken together, our data suggest that GPCR activation in response to PGF2α stimulates the mTOR pathway which increases the translational machinery in luteal cells. The translation of proteins under the control of mTOR may have implications for luteal development and regression and offer new strategies for therapeutic intervention in PGF2α-target tissues.

AB - Prostaglandin F2α (PGF2α) is an important mediator of corpus luteum (CL) regression, although the cellular signaling events that mediate this process have not been clearly identified. It is established that PGF2α binds to a G-protein coupled receptor (GPCR) to stimulate protein kinase C (PKC) and Raf-MEK-Erk signaling in luteal cells. The present experiments were performed to determine whether PGF2α stimulates the mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase 1 (S6K1) signaling pathway in steroidogenic luteal cells. We demonstrate that PGF2α treatment results in a time- and concentration-dependent stimulation of the phosphorylation and activation of S6K1. The stimulation of S6K1 in response to PGF2α treatment was abolished by the mTOR inhibitor rapamycin. Treatment with PGF2α did not increase AKT phosphorylation but increased the phosphorylation of Erk and the tumor suppressor protein tuberous sclerosis complex 2 (TSC2), an upstream regulator of mTOR. The effects of PGF2α were mimicked by the PKC activator PMA and inhibited by U0126, a MEK1 inhibitor. The activation of mTOR/S6K1 and putative down stream processes involving the translational apparatus (i.e. 4EBP1 phosphorylation, release of 4EBP1 binding in m7G cap binding assays, and the phosphorylation and synthesis of S6) were completely sensitive to treatment with rapamycin, implicating mTOR in the actions of PGF2α. Taken together, our data suggest that GPCR activation in response to PGF2α stimulates the mTOR pathway which increases the translational machinery in luteal cells. The translation of proteins under the control of mTOR may have implications for luteal development and regression and offer new strategies for therapeutic intervention in PGF2α-target tissues.

UR - http://www.scopus.com/inward/record.url?scp=33748756497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748756497&partnerID=8YFLogxK

U2 - 10.1074/jbc.M605371200

DO - 10.1074/jbc.M605371200

M3 - Article

VL - 281

SP - 26904

EP - 26913

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 37

ER -